- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05257408
Релакорилант в комбинации с Nab-паклитакселом при прогрессирующем, резистентном к платине, высокозлокачественном эпителиальном раке яичников, первичном раке брюшины или раке фаллопиевых труб
Фаза 3 исследования релакориланта в комбинации с наб-паклитакселом по сравнению с монотерапией наб-паклитакселом при прогрессирующем, резистентном к платине, высокозлокачественном эпителиальном раке яичников, первичном раке брюшины или раке фаллопиевых труб (ROSELLA)
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Обзор исследования
Статус
Подробное описание
As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.
Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
St Leonards, New South Wales, Австралия, 2065
- Site 426
-
-
Queensland
-
Benowa, Queensland, Австралия, 4217
- Site 417
-
-
Victoria
-
Melbourne, Victoria, Австралия, 3000
- Site 414
-
Melbourne, Victoria, Австралия, 3128
- Site 419
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, Аргентина, C1280AEB
- Site 393
-
Ciudad Autonoma de Buenos Aire, Buenos Aires, Аргентина, C1426ANZ
- Site 381
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Аргентина, X5004FHP
- Site 415
-
Córdoba, Córdoba Province, Аргентина, X5008 HHW
- Site 401
-
Córdoba, Córdoba Province, Аргентина, X5016
- Site 395
-
-
Mendoza Province
-
Mendoza, Mendoza Province, Аргентина, M5500AYB
- Site 404
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, 2000
- Site 391
-
Rosario, Santa Fe Province, Аргентина, S2000KDS
- Site 412
-
-
-
-
-
Aalst, Бельгия, 9300
- Site 328
-
Brussels, Бельгия, B- 1200
- Site 109
-
Charleroi, Бельгия, 6000
- Site 326
-
Hasselt, Бельгия, 3500
- Site 325
-
Leuven, Бельгия, 3000
- Site 108
-
Liège, Бельгия, B-4000
- Site 327
-
-
-
-
-
Porto Alegre, Бразилия, 90035-001
- Site 421
-
-
Brasília - DF
-
Brasília, Brasília - DF, Бразилия, 70297-400
- Site 424
-
-
Ceará
-
Fortaleza, Ceará, Бразилия, 60170-170
- Site 382
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Бразилия, 41950-640
- Site 384
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Бразилия, 30210-040
- Site 383
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Бразилия, 59062-000
- Site 390
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Бразилия, 22250-905
- Site 380
-
-
São Paulo
-
São Paulo, São Paulo, Бразилия, 01321001
- Site 376
-
São Paulo, São Paulo, Бразилия, 01327-001
- Site 389
-
São Paulo, São Paulo, Бразилия, 01409-002
- Site 413
-
São Paulo, São Paulo, Бразилия, 01509-900
- Site 374
-
São Paulo, São Paulo, Бразилия, 01509010
- Site 001
-
-
-
-
-
Budapest, Венгрия, 1122
- Site 322
-
Debrecen, Венгрия, 4032
- Site 290
-
Győr, Венгрия, 9024
- Site 348
-
-
-
-
-
Haifa, Израиль, 3436212
- Site 309
-
Jerusalem, Израиль, 911201
- Site 080
-
Tel Aviv, Израиль, 6423906
- Site 203
-
-
-
-
-
Badalona, Испания, 08916
- Site 349
-
San Sebastián, Испания, 20014
- Site 311
-
Valencia, Испания, 46026
- Site 330
-
-
-
-
-
Catania, Италия, 95126
- Site 321
-
Legnago, Италия, 37045
- Site 320
-
Milan, Италия, 20141
- Site 122
-
Pavia, Италия, 27100
- Site 295
-
Roma, Италия, 161
- Site 161
-
Rome, Италия, 00168
- Site 124
-
Torino, Италия, 10128
- Site 293
-
Treviso, Италия, 31100
- Site 319
-
-
-
-
Ontario
-
Toronto, Ontario, Канада, M4N 3M5
- Site 117
-
-
Quebec
-
Montreal, Quebec, Канада, H4A 3J1
- Site 273
-
-
-
-
-
Gdynia, Польша, 81-519
- Site 341
-
Poznan, Польша, 61-886
- Site 331
-
Siedlce, Польша, 08-110
- Site 329
-
-
-
-
-
Cheltenham, Соединенное Королевство, GL53 7AN
- Site 366
-
London, Соединенное Королевство, NW1 2PG
- Site 055
-
Manchester, Соединенное Королевство, M20 4BX
- Site 344
-
Northwood, Соединенное Королевство, HA6 2RN
- Site 345
-
-
East Sussex
-
Brighton, East Sussex, Соединенное Королевство, BN2 1ES
- Site 367
-
-
Somerset
-
Taunton, Somerset, Соединенное Королевство, TA1 5DA
- Site 351
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85016
- Site 318
-
Tucson, Arizona, Соединенные Штаты, 85719
- Site 277
-
-
California
-
Irvine, California, Соединенные Штаты, 92618
- Site 350
-
La Jolla, California, Соединенные Штаты, 92093
- Site 364
-
Palo Alto, California, Соединенные Штаты, 94304
- Site 150
-
San Francisco, California, Соединенные Штаты, 94109
- Site 278
-
San Francisco, California, Соединенные Штаты, 94143
- Site 014
-
Solvang, California, Соединенные Штаты, 93463
- Site 316
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Site 032
-
-
Florida
-
Miami Beach, Florida, Соединенные Штаты, 33140
- Site 335
-
Weston, Florida, Соединенные Штаты, 33331
- Site 042
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Site 009
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Site 272
-
Gainesville, Georgia, Соединенные Штаты, 30548
- Site 372
-
Savannah, Georgia, Соединенные Штаты, 31405
- Site 291
-
-
Illinois
-
Evanston, Illinois, Соединенные Штаты, 60201
- Site 315
-
Hinsdale, Illinois, Соединенные Штаты, 60521
- Site 314
-
Urbana, Illinois, Соединенные Штаты, 61801
- Site 346
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46260
- Site 339
-
-
Kansas
-
Overland Park, Kansas, Соединенные Штаты, 66211
- Site 200
-
Overland Park, Kansas, Соединенные Штаты, 66211
- Site 334
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40241
- Site 279
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Site 128
-
-
New Jersey
-
New Brunswick, New Jersey, Соединенные Штаты, 08901
- Site 288
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87131
- Site 292
-
-
New York
-
Flushing, New York, Соединенные Штаты, 11355
- Site 275
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45242
- Site 298
-
Cincinnati, Ohio, Соединенные Штаты, 45459
- Site 304
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97210
- Site 280
-
Portland, Oregon, Соединенные Штаты, 97213
- Site 317
-
Portland, Oregon, Соединенные Штаты, 97239
- Site 049
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Соединенные Штаты, 18015
- Site 337
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
- Site 127
-
-
South Dakota
-
Rapid City, South Dakota, Соединенные Штаты, 57701
- Site 276
-
-
Tennessee
-
Germantown, Tennessee, Соединенные Штаты, 38138
- Site 368
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Site 281
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78731
- Site 229
-
Bedford, Texas, Соединенные Штаты, 76022
- Site 312
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Site 297
-
San Antonio, Texas, Соединенные Штаты, 78240
- Site 392
-
The Woodlands, Texas, Соединенные Штаты, 77380
- Site 301
-
-
Virginia
-
Norfolk, Virginia, Соединенные Штаты, 23502
- Site 300
-
Richmond, Virginia, Соединенные Штаты, 23298
- Site 365
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Site 121
-
-
-
-
-
Lille, Франция, 59020
- Site 306
-
Montpellier, Франция, 34298
- Site 347
-
Nancy, Франция, 54100
- Site 307
-
Nice, Франция, 06189
- Site 310
-
Paris, Франция, 75015
- Site 289
-
Plérin, Франция, 22190
- Site 323
-
-
-
-
-
Gyeonggi-do, Южная Корея, 10408
- Site 397
-
Seoul, Южная Корея, 03080
- Site 399
-
Seoul, Южная Корея, 03722
- Site 398
-
Seoul, Южная Корея, 05505
- Site 403
-
Seoul, Южная Корея, 06273
- Site 400
-
Seoul, Южная Корея, 06351
- Site 396
-
Seoul, Южная Корея, 08308
- Site 402
-
Seoul, Южная Корея, 42601
- Site 409
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
- Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
- Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
- Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
- Has a life expectancy of ≥3 months.
- At least one lesion that meets the definition of measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Able to comply with protocol requirements.
- Able to swallow and retain oral medication and does not have uncontrolled emesis.
- Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
- Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
- Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
- Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.
Exclusion Criteria:
- Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
- Has had any major surgery within 4 weeks prior to randomization.
- Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
- Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
- Has not received prior bevacizumab treatment.
- Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
- Has received wide-field radiation to more than 25% of marrow-bearing areas.
- Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
- Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
- Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
- Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
- Has peripheral neuropathy from any cause >Grade 1.
- Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
- Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
- Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
- Has any untreated or symptomatic central nervous system (CNS) metastases.
- Patients with a history of other malignancy within 3 years prior to randomization.
- Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
- Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
- Has received a live vaccine within 30 days prior to the study start date.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2
Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1. |
Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.
Другие имена:
Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
|
Активный компаратор: Nab-paclitaxel 100 mg/m^2
Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle. |
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Временное ограничение: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions. |
Up to 20 months
|
|
Overall Survival
Временное ограничение: Up to 32 months
|
Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates. |
Up to 32 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
PFS as Assessed by the Investigator
Временное ограничение: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 20 months
|
|
Objective Response as Assessed by the Investigator
Временное ограничение: Up to 20 months
|
Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Up to 20 months
|
|
Best Overall Response as Assessed by the Investigator
Временное ограничение: Up to 20 months
|
Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1. |
Up to 20 months
|
|
Duration of Confirmed Responses as Assessed by the Investigator
Временное ограничение: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first. |
From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
|
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Временное ограничение: 24 weeks
|
Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator. |
24 weeks
|
|
Cancer Antigen (CA)-125 Response
Временное ограничение: Up to 24 months
|
CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders. |
Up to 24 months
|
|
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Временное ограничение: Up to 15 months
|
Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria. |
Up to 15 months
|
|
Number of Patients With One or More Adverse Events
Временное ограничение: Up to 22 months
|
Up to 22 months
|
|
|
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Временное ограничение: Up to 25 months
|
Up to 25 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics
Публикации и полезные ссылки
Общие публикации
- Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 Oct 20;41(30):4779-4789. doi: 10.1200/JCO.22.02624. Epub 2023 Jun 26.
- Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balazs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagameri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2.
- Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagameri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet. 2026 Apr 18;407(10538):1513-1524. doi: 10.1016/S0140-6736(26)00462-9. Epub 2026 Apr 10.
- Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Glaz A, Devaux A, Gladieff L, Gordinier ME, Korach J, McCollum ME, Mileshkin L, Monk BJ, Nicum S, Nogueira-Rodrigues A, Oaknin A, O'Malley DM, Orlando M, Dreiling L, Tudor IC, Lorusso D. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. J Gynecol Oncol. 2024 Jul;35(4):e111. doi: 10.3802/jgo.2024.35.e111.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Заболевания эндокринной системы
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Заболевания половых органов, Женский
- Новообразования эндокринных желез
- Заболевания яичников
- Заболевания придатков
- Генитальные Новообразования, Женщины
- Заболевания гонад
- Перитонеальные заболевания
- Новообразования брюшной полости
- Заболевания фаллопиевых труб
- Новообразования яичников
- Новообразования брюшины
- Новообразования фаллопиевых труб
- 130-нм-паклитаксел
- релакорилант
Другие идентификационные номера исследования
- CORT125134-556
- GOG-3073 (Другой идентификатор: Gynecologic Oncology Group)
- ROSELLA Study 556 (Другой идентификатор: Corcept Therapeutics)
- ENGOT-OV72 (Другой идентификатор: European Network of Gynaecological Oncological Trial Groups)
- APGOT-Ov10 (Другой идентификатор: Asia-Pacific Gynecologic Oncology Trials Group)
- LACOG 0223 (Другой идентификатор: Latin American Cooperative Oncology Group)
- ANZGOG2221/2023 (Другой идентификатор: Australia New Zealand Gynaecological Oncology Group)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .